End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
630.2 INR | +1.56% | -2.79% | -12.80% |
Mar. 27 | Suven Pharmaceuticals Limited Announces Shifting of Registered Office | CI |
Mar. 05 | Transcript : Cohance Lifesciences Limited, Suven Pharmaceuticals Limited - M&A Call |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- With an expected P/E ratio at 39.39 and 47.93 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.80% | 1.9B | D- | ||
+38.11% | 723B | C+ | ||
+34.28% | 595B | B | ||
-4.46% | 369B | C+ | ||
+20.12% | 332B | B- | ||
+2.80% | 282B | C+ | ||
+17.02% | 244B | B+ | ||
+9.31% | 208B | B- | ||
-5.07% | 205B | A+ | ||
+0.02% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SUVENPHAR Stock
- Ratings Suven Pharmaceuticals Limited